DACRIN research - underway

Open to recruitment

Looking to participate in a DACRIN study? Below are links to eligibility information, participating organisations, and contact details for all currently open trials. Additionally, we offer an online search tool called ClinTrial Ref, which can help clinicians and patients you easily find the right study.

Study title	Lead group	Study details
DACRIN 2022-1: A placebo-controlled randomised trial of cannabidiol (CBD) in the treatment of cannabis use disorder	DACRIN (SESLHD)	Australia New Zealand Clinical Trials Registry ACTRN12623000526673
DACRIN 2021-4: The National Australian HCV Point-of-Care Testing Program (HCVPOCT). DACRIN contributing participants.	The Kirby Institute	ClinicalTrials.gov NCT05042544
DACRIN 2021-3: Enhancing hepatitis C testing and treatment among people who inject drugs attending needle and syringe programs (TEMPO). DACRIN contributing participants	The Kirby Institute	ClinicalTrials.gov NCT04014179
DACRIN 2021-1: Impact of long-acting depot buprenorphine on the high-risk post release period for people with opioid dependence (The Release Study)	DACRIN (HNELHD)	Contact us

Closed to recruitment

Our ongoing data collection continues even though we are no longer accepting new participants for these DACRIN studies.

Study title	Lead group	Study details
DACRIN 2019-3: Examining clinical outcomes and quality indicators for clients attending NSW public alcohol and other drug (AOD) treatment services (COQI Cohort Study)	DACRIN (SESLHD)	COQI Program
DACRIN 2017-5: ETHOS Engage: Enhancing treatment of Hepatitis C in Opioid Substitution Setting II (ETHOS II) partnership project to enhance hepatitis C care in drug and alcohol clinics	The Kirby Institute	Conway, Valerio et al. 2021 Valerio, Alavi et al. 2021 Conway, Valerio et al. 2022 Valerio, Alavi et al. 2022

Analyses underway

The data collection phase of the DACRIN studies below has been successfully completed. Our researchers or partners are currently working on analysing the data and preparing manuscripts for publication.

Study title	Lead group	Study details
DACRIN 2022-4: Investigating staff attitudes, knowledge, and perspectives regarding cannabis use by clients in NSW Opioid Treatment Programs: A Staff Survey	DACRIN (SESLHD)	Contact us
DACRIN 2022-3: Case Mix Variables Project	University of Wollongong	Contact us
DACRIN 2021-2: Microdosing with buprenorphine to transfer from methadone to buprenorphine in adults with opioid dependence - a prospective non-randomised open label clinical trial	DACRIN (SLHD)	Australia New Zealand Clinical Trials Registry ACTRN12622000444785
DACRIN 2020-5: Characterizing withdrawal from depot buprenorphine: an observational case series of withdrawal from Buvidal	DACRIN (SESLHD)	Australia New Zealand Clinical Trials Registry ACTRN12621001011875
DACRIN 2020-4: A trial of the effectiveness of vaporised nicotine products (VNPs) for smoking cessation amongst NSW opiate agonist treatment (OAT) clients – HARMONY study.	DACRIN (HNELHD)	Australia New Zealand Clinical Trials Registry ACTRN12621000148875
DACRIN 2019-6: Alcohol and Other Drugs (AOD) client concerns and wishes regarding cognitive impairment treatment (AOD Cog)	DACRIN (NLHD)	Contact us
DACRIN 2019-4: Driving perspectives, behaviours and concerns of consumers receiving opioid treatment	DACRIN (SLHD)	Contact us
DACRIN 2019-2: Developing a clinical data laboratory for methamphetamine use in NSW: the MAData project.	DACRIN (SESLHD)	Black, Mammen et al. 2022 Black, Bruno et al. 2023
DACRIN 2016-5: Improving alcohol treatment outcomes: The impact of client, intervention and system variables on treatment outcomes (Alcohol Treatment Centre study)	University of Newcastle	Contact us
DACRIN 2016-3: A randomised double-blind placebo-controlled study of lisdexamphetamine for the treatment of methamphetamine dependence (The LiMA study)	DACRIN (SVHN)	Ezard, Dunlop at al. 2018